The long road: improving outcome in elderly "unfit" AML?Lowenberg, B. & Huls, G., 11-Jun-2020, In : Blood. 135, 24, p. 2114-2115 3 p.
Research output: Contribution to journal › Editorial › Academic › peer-review
In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.
|Number of pages||3|
|Publication status||Published - 11-Jun-2020|
- LOW-DOSE CYTARABINE, PLACEBO